Metabolomic Profiles in Patients with Cervical Cancer Undergoing Cisplatin and Radiation Therapy

Overview

Journal Biomol Ther (Seoul)

Specialty Pharmacology

Date 2024 Apr 8

PMID 38586913

Authors

Seo-Yeon Choi

Suin Kim

Ji-Young Jeon

Min-Gul Kim

Sun-Young Lee

Kwang-Hee Shin

Affiliations

Soon will be listed here.

Abstract

This study was aimed to evaluate endogenous metabolic changes before and after cisplatin and radiation therapy in patients with cervical cancer via untargeted metabolomic analysis using plasma samples. A total of 13 cervical cancer patients were enrolled in this study. Plasma samples were collected from each patient on two occasions: approximately one week before therapy (P1) and after completion of cisplatin and radiation therapy (P2). Of the 13 patients, 12 patients received both cisplatin and radiation therapy, whereas one patient received radiation therapy alone. The samples were analyzed using the Ultimate 3000 coupled with Q Exactive Focus Hybrid Quadrupole-Orbitrap mass spectrometry (Thermo Fisher Scientific, Waltham, MA, USA). Chromatographic separation utilized a Kinetex C18 column 2.1×100 mm (2.6 μm) (Phenomenex, Torrance, CA, USA), and the temperature was maintained at 40°C. Following P2, there were statistically significant increases in the concentrations of indoxyl sulfate, phenylacetylglutamine, Lysophosphatidyethanolamine (LysoPE) (18:1), and indole-3-acetic acid compared with the concentrations observed at P1. Specifically, in the human papillomavirus (HPV) noninfection group, indoxyl sulfate, LysoPE (18:1), and phenylacetylglutamine showed statistically significant increases at P2 compared with P1. No significant changes in metabolite concentrations were observed in the HPV infection group. Indoxyl sulfate, LysoPE (18:1), phenylacetylglutamine, and indole-3-acetic acid were significantly increased following cisplatin and radiation therapy.

References

Kihara Y, Mizuno H, Chun J . Lysophospholipid receptors in drug discovery. Exp Cell Res. 2014; 333(2):171-177. PMC: 4408218. DOI: 10.1016/j.yexcr.2014.11.020. View

Holditch S, Brown C, Lombardi A, Nguyen K, Edelstein C . Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury. Int J Mol Sci. 2019; 20(12). PMC: 6627318. DOI: 10.3390/ijms20123011. View

Tan B, Chen J, Qin S, Liao C, Zhang Y, Wang D . Tryptophan Pathway-Targeted Metabolomics Study on the Mechanism and Intervention of Cisplatin-Induced Acute Kidney Injury in Rats. Chem Res Toxicol. 2021; 34(7):1759-1768. DOI: 10.1021/acs.chemrestox.1c00110. View

Chen H, Zhang J, Zhou H, Zhu Y, Liang Y, Zhu P . UHPLC-HRMS-based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer. Front Oncol. 2022; 12:934145. PMC: 9366052. DOI: 10.3389/fonc.2022.934145. View

Bourmaud A, Gallien S, Domon B . Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: Principle and applications. Proteomics. 2016; 16(15-16):2146-59. DOI: 10.1002/pmic.201500543. View

Schwickert G, Walenta S, Sundfor K, Rofstad E, Mueller-Klieser W . Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 1995; 55(21):4757-9. View

Sui Y, Yang Y, Wang J, Li Y, Ma H, Cai H . Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells. Biomed Res Int. 2015; 2015:598386. PMC: 4558435. DOI: 10.1155/2015/598386. View

Wei Y, Wang J, Chen F, Li X, Zhang J, Shen M . Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma. Front Oncol. 2022; 12:808290. PMC: 8919723. DOI: 10.3389/fonc.2022.808290. View

Wood P, Hrushesky W . Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995; 95(4):1650-9. PMC: 295669. DOI: 10.1172/JCI117840. View

10.

Ji Y, Yin W, Liang Y, Sun L, Yin Y, Zhang W . Anti-Inflammatory and Anti-Oxidative Activity of Indole-3-Acetic Acid Involves Induction of HO-1 and Neutralization of Free Radicals in RAW264.7 Cells. Int J Mol Sci. 2020; 21(5). PMC: 7084870. DOI: 10.3390/ijms21051579. View

11.

Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X . Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016; 10:1885-95. PMC: 4907638. DOI: 10.2147/DDDT.S106412. View

12.

Shi W, Yuan X, Cui K, Li H, Fu P, Rehman S . LC-MS/MS Based Metabolomics Reveal Candidate Biomarkers and Metabolic Changes in Different Buffalo Species. Animals (Basel). 2021; 11(2). PMC: 7924386. DOI: 10.3390/ani11020560. View

13.

Zhu Z, Qi Z, Zhang J, Xue W, Li L, Shen Z . Untargeted Metabolomics Analysis of Esophageal Squamous Cell Carcinoma Discovers Dysregulated Metabolic Pathways and Potential Diagnostic Biomarkers. J Cancer. 2020; 11(13):3944-3954. PMC: 7171502. DOI: 10.7150/jca.41733. View

14.

Chhonker Y, Kanvinde S, Ahmad R, Singh A, Oupicky D, Murry D . Simultaneous Quantitation of Lipid Biomarkers for Inflammatory Bowel Disease Using LC-MS/MS. Metabolites. 2021; 11(2). PMC: 7918109. DOI: 10.3390/metabo11020106. View

15.

Putral L, Bywater M, Gu W, Saunders N, Gabrielli B, Leggatt G . RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol. 2005; 68(5):1311-9. DOI: 10.1124/mol.105.014191. View

16.

Badaracco G, Savarese A, Micheli A, Rizzo C, Paolini F, Carosi M . Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer. Oncol Rep. 2010; 23(4):1093-9. DOI: 10.3892/or_00000737. View

17.

Yuan C, Filippova M, Duerksen-Hughes P . Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses. 2012; 4(12):3831-50. PMC: 3528293. DOI: 10.3390/v4123831. View

18.

Gadducci A, Tana R, Cosio S, Genazzani A . The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2007; 66(1):10-20. DOI: 10.1016/j.critrevonc.2007.09.002. View

19.

Cheng T, Ma M, Liao M, Zheng C, Lu K, Liao C . Indoxyl Sulfate, a Tubular Toxin, Contributes to the Development of Chronic Kidney Disease. Toxins (Basel). 2020; 12(11). PMC: 7693919. DOI: 10.3390/toxins12110684. View

20.

Kwon B . A metabolite of the gut microbiota: a facilitator of chemotherapy efficacy in cancer. Signal Transduct Target Ther. 2023; 8(1):238. PMC: 10250301. DOI: 10.1038/s41392-023-01506-4. View